Analyze and apply the newest clinical guidelines and treatments related to lipids, cardiovascular health, fatty liver and kidney disease and more with AACE’s course on Cardiometabolic and Lipid Strategies for Endocrinologists. Key experts provide evidenced-based strategies and assessment of nonpharmacologic and pharmacologic therapies in cardiometabolic and lipid health to elevate patient care.
Take your cardiometabolic and lipid knowledge to the next level! This collection of lectures features the most recent and relevant topics in the field of endocrinology. This online course contains video lectures, assessment questions, and the opportunity for CME and MOC!
Starts 7/21/2022 | Expires 7/21/2023
- Triglyceride as a Factor in Residual CVD Risk - Eliot A. Brinton, MD
- Disease State Network Year-in-Review: Lipids and CV Health - Vishnu Priya Pulipati, MD; Eliot A. Brinton, MD; Betul Hatipoglu, MD
- Cardiometabolic Effects of Fatty Kidney Disease - Christian W. Mende, MD
- Cardiovascular Disease and Diabetes: Assessing Risks and Prioritizing Therapies - Peter Reaven, MD
- Nonalcoholic Fatty Liver Guideline - Scott Isaacs, MD, FACP, FACE; Romina Lomonaco, MD; Kenneth Cusi, MD, FACP, FACE
- The New Biology of Pheochromocytomas - Karel Pacak, MD, PhD, DSc, FACE
Upon completion of the activity, participants should be able to:
- Discuss the prevalence and importance of mild to moderate elevations of fasting triglycerides (TG) as a risk factor for atherosclerotic cardiovascular disease (ASCVD) and implement appropriate criteria for use of prescription icosapent ethyl (IPE) in ASCVD prevention
- Evaluate the recent advances in lipids and cardiovascular risk factors during 2021-2022
- Recognize factors of Fatty Kidney Disease and address imaging and therapies for treatment
- Discuss the role of glucose control on cardiovascular outcomes in type 2 diabetes and identify the glucose lowering medications most effective in reducing cardiovascular risk
- Outline the newest clinical and basic discoveries related to hereditary pheochromocytoma and paraganglioma as well as newest imaging guidelines and treatment options
Eliot A. Brinton, MD, FAHA, FNLA, FACE
Betul Hatipoglu, MD
Vishnu Priya Pulipati, MD
Christian W. Mende, MD
Peter Reaven, MD
Scott Isaacs, MD, FACP, FACE
Romina Lomonaco, MD
Kenneth Cusi, MD, FACP, FACE
Karel Pacak, MD, PhD, DSc, FACE
This educational initiative is intended for Endocrinologists.
The American College of Endocrinology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Endocrinology designates this enduring activity for a maximum of 6.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.0 MOC Medical Knowledge point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC point(s) equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.
Disclosures/Conflicts of Interest
In accordance with the ACCME Standards for Commercial Support, The American Association of Clinical Endocrinology (AACE) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. AACE resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, AACE seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. AACE is committed to providing learners with high-quality CME.
Activity Staff Disclosures
The planners, reviewers, editors, staff, CME committee, and other members at the American Association of Clinical Endocrinology who control content have no relevant financial relationships to disclose.
|Eliot||A.||Brinton||MD, FACE, FAHA, FNLA||President||Utah Lipid Center||Speaker||89bio (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- January 1, 2021); Amarin (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Honorarium (Status: Ongoing), Research Support (Status: Ongoing); Amgen (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Honorarium (Status: Ongoing); Amryt (Self) : Honorarium (Status: Ongoing); Dalcor (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Esperion (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- August 1, 2021), Honorarium (Status: Terminated --- August 1, 2021); Genzyme () : Speaker's Bureau; Kowa (Self) : Grant/Research Support (Status: Ongoing); Merck () : Consultant, Speaker's Bureau; Novartis (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Pfizer (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing)|
|Christian||W.||Mende||MD||Clinical Professor of Medicine||UCSD||Speaker||Bayer, AstraZeneca, Lilly, Boehringer (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Honorarium (Status: Ongoing)|
|Peter||Reaven||MD||Professor of Clinical Medicine||University of Arizona, Phoenix||Speaker||AstraZeneca (Self) : Research Grant (Status: Terminated --- july 2021); Dexcom (Self) : Research Grant (Status: Ongoing)|
|Cecilia||C.||Low Wang||MD||Professor of Medicine||University of Colorado Anschutz Medical Campus School of Medicine||Moderator||Dexcom Inc (Self) : Research Grant (Status: Ongoing)|
|Oksana||Hamidi||DO||Endocrinologist||UT Southwestern Medical Center||Moderator||Corcept Therapeutics Inc (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- March 2020); Novo Nordisk (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- October 2020); Stongbridge Pharma (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- Nov 2020)|
Disclosure of Unlabeled Use
AACE requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. AACE does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
The American Association of Clinical presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The American Association of Clinical Endocrinology assumes no liability for the information herein.